Aligos Therapeutics, Inc. (ALGS)

Aligos Therapeutics' stock price has experienced fluctuations, including a decline of 54.04% from November 2024 to November 2025, followed by a gain of 3.31% on November 24, 2025, and a 38.2% increase over the two weeks prior. Key events impacting the stock include the initiation of the Phase 2 B-SUPREME study for ALG-000184, positive data presentations for ALG-000184 and ALG-055009, presentations at upcoming conferences, and a potential dilution risk from a $400M mixed-shelf offering in December 2024.

As a clinical-stage biopharmaceutical company, Aligos Therapeutics' products are still in development, resulting in no typical demand seasonality. Demand for its research and development efforts is driven by the ongoing global medical need for treatments for chronic diseases and viral infections, rather than seasonal patterns.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic liver diseases and viral infections, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections. Its pipeline includes ALG-000184 (Pevifoscorvir), a capsid assembly modulator (CAM-E) in Phase 2 trials for chronic HBV infection; ALG-055009, an oral THR-β agonist for MASH showing liver fat reduction in Phase 2a trials; and ALG-097558, a protease inhibitor targeting coronavirus infections, with a Phase 2 study being funded in the U.K. The company also has preclinical programs targeting hepatitis B and hepatitis delta viruses.

Aligos Therapeutics is headquartered in South San Francisco, California, and has offices in Leuven, Belgium, and Shanghai, China. Clinical trials for ALG-000184 have global regulatory approvals in countries including the US, China, Canada, Taiwan, UK, New Zealand, and Moldova.

Aligos Therapeutics has actively participated in healthcare conferences, presenting research and pipeline developments. Positive clinical data for drug candidates like ALG-000184 and ALG-055009 positively influence the company's reputation. Analyst coverage indicates a consensus "Hold" rating for the stock. The company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) in November 2025.

Aligos Therapeutics is owned by a mix of institutional investors (26.15%), insiders (10.37%), and retail investors (63.48%). Major institutional shareholders include Woodline Partners LP, Deep Track Capital, LP, and Alyeska Investment Group, L.P., among others.